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A simple model for the simultaneous passive membrane transport and 
bioconversion of a drug, which may be a weak electrolyte or a neutral 
molecule, is mathematically described. It includes an aqueous diffusion 
layer and an operational aqueous pore pathway. The applicability of the 
model is shown for the in situ rat intestinal transport of prostaglandin Fpa. 
1. Introduction 
The occurrence of the simultaneous membrane transport and bioconversion 
of drugs in the intestinal tract comes as no surprise in view of the fact that 
many enzyme systems are found on the membrane surface and within the 
intestinal membrane and enterocyte. In quantitative and mechanistic studies 
on the simultaneous transport and bioconversion of solute molecules across 
the intestinal barrier, a path length of approximately 20 l.trn from the mucosal 
surface to the blood capillary bed, it is prerequisite that one distinguishes 
between cavital, membrane and intracellular digestion. Ugolev (1968. 1974) 
and Crane (1975) have expressed various viewpoints on membrane digestion 
in dealing, particularly, on the digestion of carbohydrates. However, the 
broad implication with respect to solute molecules such as drugs is that 
there are two possible membrane metabolic situations for consideration. One 
is the existence of surface-bound enzymes oriented toward the aqueous 
environment of the intestinal lumen leading to membrane contact digestion. 
Here, the enzyme systems found in the glycocalyx are also included. The other 
is the location of the relevant enzyme system within the membrane. 
Using salicylamide as the model substrate, Barr & Riegelman (1970) 
studied the intestinal salicylamide glucuronide formation and transport in 
the rabbit with in vitro cannulated everted intestines and in vioo perfused 
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closed loops with complete mesenteric venous blood collection and examined 
some theoretical physical models. Magee, Armour & Miller (1973) showed 
that the absorption of the prostaglandin F,, and E2 acids and the 15-methyl- 
Fza methyl ester is accompanied by extensive metabolism by the small 
intestines of the rat. Similar results were found in absorption experiments 
using intact intestinal loops of dogs (Robert, Magee, Miller & Nezamis, 
1974). Using [l- 14C] prostaglandin E,, Parkinson & Schneider (1969) 
found that only minute amounts of the intact weak acid survived the transport 
from the mucosal to the serosal fluid of rat jejunum segments in vitro. They 
attributed the loss of the “C-label to an oxidative process leading to the 
formation of carbon dioxide. Prostaglandin E, is metabolized by homo- 
genates of both rat and dog stomach and jejunum (Nakano, Prancan & 
Morsy, 1973). 
The purpose of this paper is to present a simple physical model for the 
simultaneous drug transport and bioconversion across the intestinal mem- 
brane. The model is derived from well-established physicochemical concepts 
with the accompanying mathematics and is described in such a manner 
that it provides the basis for the design of experiments and interpretation 
of data for obtaining quantitative estimates of meaningful phenomeno- 
logical parameters. Specifically, the model is directed to the intestinal 
transport of the natural prostaglandins. 
2. General Description of the Physical Model 
The physical model for the simultaneous transport and bioconversion of 
a drug, taken here as a weak acid, is shown in Fig. 1. It consists of an aqueous 
diffusion layer (often referred to as the unstirred aqueous layer) in the lumen 
in series with the intestinal membrane barrier followed by the blood sink. 
Operationally, the membrane is comprised of two parallel pathways: the 
simultaneous diffusional transport-bioconversion pathway in the lipoidal 
fraction of the membrane and the aqueous pore pathway. It is assumed that 
(a) quasi-steady state conditions prevail, (b) metabolism in the lumenal 
solution, if it occurs, is insignificant, (c) only non-dissociated drug species 
are able to partition into the lipoidal fraction of the membrane, (d) metabolism 
occurs homogeneously within the membrane and, consequently, no significant 
metabolism is assumed to occur with membrane surface enzymes, (e) the 
transport of non-dissociated and anionic drug species across the aqueous 
pores occurs with equal facility, (f) iso-osmotic conditions exist everywhere, 
(g) the aqueous diffusion coefficients of non-dissociated and anionic drug 
species are identical and (h) sink conditions prevail on the blood side. It is 
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FIG. 1. Physical model for the simultaneous intestinal membrane transport and biocon- 
version of a substrate drug. An aqueous diffusion layer in the intestinal umen is in series 
with the membrane consisting of two parallel pathways: the diffusional transport-biocon- 
version pathway and the aqueous pore pathway. The model depicts the boundary concen- 
trations and distances. 
also taken here that since the radii of curvature of the aqueous diffusion 
layer and the membrane are not too different from each other, the planar 
model is applicable (Flynn, Ho & Higuchi, 1976). 
3. Steady-State Fluxes 
The total flux of the drug (weak acid) across the aqueous diffusion layer is 
J,, =;A (C,-C,) = Pa&,-C,), (1) 
aq 
Jag = total flux in the aqueous diffusion layer per unit area. 
D,,q = aqueous diffusion coefficient, cm2 s-l. 
La4 = effective thickness of the aqueous diffusion layer. 
P,,q = permeability coefficient (= Daq/L,,), cm s-‘. 
C,, C, = total concentration of non-dissociated and anionic species in the 
bulk lumenal solution and at the membrane surface. 
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The quasi-steady state change in the concentration in the membrane with 
distance x is given by the following expression which describes the simul- 




D = diffusion coefficient in the membrane, cm2 s-l. 
k = apparent first-order enzyme rate constant, s- ‘. 
C = concentration in the membrane. 
L = thickness of the membrane. 
With the boundary conditions, 
C = Ci,,atx = 0 
C=Oatx= -L 
the solution to equation (2) is 
c _ CE ,,, sinh COWL + 41 
sinh (Ld’m) 
(3) 
where Cz,,, = concentration of non-dissociated species at the surface on the 
membrane side. Thus, the concentration of the intact drug in the membrane 
decreases exponentially with distance. The pathway of the membrane flux 
across the diffusional transport-bioconversion is obtained by integrating 
equation (2) once; accordingly, 
constant = D g + k j C dx. (4) 
Using equation (3), 




J,,, = flux in the membrane per unit apparent surface area. 
c:nl = concentration of non-dissociated species at the surface on the 
membrane side. 
M = volume fraction of lipoidal phase of the membrane. 
The flux of the total concentration of drug per unit area across the aqueous 
pores of the membrane into the blood sink is 
J 
P 
= Cl -cc)D,cs = y 
L 
C 
P S’ (6) 
Jp = flux per unit apparent surface area across the pores. 
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(1 -LX) = volume fraction of aqueous pores of the membrane. 
D, = diffusion coefficient in the pores, cm* s-l. 
L = thickness of the membrane. 
Pp = permeability coefficient of the pores [ = (I- (x)0,/L] cm s- ’ . 
Here, it is taken that there is no metabolism occurring in the aqueous pore 
pathway. 
The continuity of flow across the membrane interface is 
J,, = (J,L=, +Jp. (7) 
The lipoidal membrane-water partition coefficient is 
cl en K = co- = -c6- (8) 
s P 
K = partition coefficient. 
C’s0 = concentration of non-dissociated species at the membrane surface on 
the lumen side. 
The fraction of non-dissociated species? of the weak acid is given by 
(9) 
X, = fraction of non-dissociated species at the membrane surface. 
KG = dissociation constant. 
(H+), = hydrogen ion concentration at membrane surface. 
After combining equations (1) and (5)-(9) and algebraic rearrangement, the 
total concentration at the membrane surface on the lumen side is explicitly 
related to the total concentration of drug in the bulk lumenal solution by 
whereupon equation (1) becomes 
Since 
(10 
7 For a weak base, X, = l/(1 -1 (H+),/&) and for a neutral molecule, X, = 1. 
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V = volume of solution. 
A = apparent surface area. 








P+ aq ctKX,xjkD 
__ +PP tanh (d/c/D) 
Integrating between the initial total concentration C, (0) and C (t) one 
obtains the semi-logarithmic expression : 
In C, = In C,(O) - K,t. (1% 
4. Special Case of Simple Passive Transport 
In the special case when there is an insignificant occurrence or absence of 
bioconversion during the passive transport across the membrane, i.e. k < D, 
the tanh (&/k/D) term in equation (14) converges to zero, and consequently, 
gives an apparent impression that there is no passive membrane transport. 
Physically, this is inconsistent. However, letting u = LJk/D < 1.0, the 
series expansion leads to 
tanhu=u+... (u Q 1.0) (16) 
in which the higher terms are small and inconsequential. It follows that 
lim tanhu L 
U-r0 
JE ‘ii (17) 
and also equation (14) reduces to a familiar expression (Ho, Higuchi & Turi, 
1972) : 
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5. Factorization of the Effective Transport-bioconversion 
Permeability Coefficient 
It is possible to gain a further quantitative insight into the simultaneous 
diffusion and enzymatic bioconversion phenomena in the membrane. Let the 
effective membrane passive transport-bioconversion permeability coefficient 
(I’:.,,) be defined by 
p:,llt = aKX,JkD ----+P, _. 
tanh (LJk/D) 
iW 




e,m =- s + P, L 
Gw 
at a constant pH, the ratio of equations (19) and (20) is 
K,m-pp) L&ID 
(P,, m -PP) = tanh (LJk/D) 
from which the term LJkID is readily calculated since P&,,, P,,, and Pp 
are experimentally determined coefficients. The substitution of this calculated 
term into the argument of the tanh function in equation (19) leads to 
I---- 
orK~~ = K, ,,, -$1 tanh (Ld k/D) __- 
XS 
(22) 
where ctKdkD, having units of cm s-l, ’ IS physically the intrinsic membrane 
transport-bioconversion permeability coefficient. The experimental approach 
in accomplishing the factorization involves the carrying out of absorption 
studies in the absence and presence of relevant enzyme inhibitors. 
6. Relevance of the Physical Model to Absorption Experiments 
The physical model predicts that the total concentration of the weak acid 
drug in the intestinal lumen decreases logarithmically with time. As seen in 
equation (14), the slope will be influenced by the buffer pH of the solution 
and the hydrodynamics of the solution in the lumen. At low pH (< pK,) 
the concentration of non-dissociated species is high and the rate constant 
will be larger as compared to that at a higher pH. However, when the 
pH % pK,, the rate constant will attain a minimum asymptotic value 
operationally indicative of the transport of the anionic species across the 
aqueous pores of the membrane. Because of the influence of the hydro- 
dynamics on the effective thickness of the aqueous diffusion layer (La,), 
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the permeability coefficient of the aqueous boundary layer (P,,) will be 
larger when the solution is agitated than the corresponding permeability 
coefficient when the solution is less agitated. Consequently, the absorption 
rate will be faster with higher degrees oI&gitation under the conditions when 
the total absorption rate is at least 25% influenced by diffusion across the 
unstirred aqueous layer in front of the membrane. It is expected that 
the degree of hydrodynamics will have an insignificant effect on the 
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FIG. 2. Apparent first order absorption rate constant versus buffer pH profiles of prosta- 
glandin Fatr at two different hydrodynamic conditions from in sits absorption experiments 
in the rat jejunum. 
The experimental evidence for the physical model described herein is 
shown in Fig. 2. It involves the simultaneous transport and metabolism of 
prostaglandin Fzg (PGF2& across the jejunal membrane of the rat using an 
in situ non-perfusion technique?. The apparent first-order absorption rate 
constant Ku versus pH profiles at two hydrodynamic situations show the 
physicalinteractions between the pH and permeabilities of theaqueousdiffusion 
t Manuscript on the experimental description and data analysis for factorization of the 
physical transport parameters is in progress. 
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layer, passive transport-bioconversion pathway and aqueous pores. Quali- 
tative analyses of the plasma fraction of blood from the portal vein by high 
pressure liquid chromatography and thin layer chromatography indicate the 
presence of 1 Sketo-PGF,, and 15-keto-13,14-dihydro-PGF,, and the absence 
of PGF,,. Experimental studies are continuing with other natural prosta- 
glandins and their esters. 
7. Summary 
A physical model for the intestinal transport of solutes has been described 
in which an aqueous diffusion layer barrier is in series with the membrane 
barrier consisting of a passive diffusional-bioconversion pathway and an 
operational aqueous pore pathway in parallel. It provides the basis for the 
experimental design of in situ studies and quantification of physically 
meaningful and experimentally accessible transport and overall bioconversion 
kinetic parameters. The interaction and factorization of (a) the permeability 
coefficients of the aqueous diffusion layer, aqueous pores of the membrane 
and the principal membrane transport-bioconversion pathway and (b) the 
pH and pK, and (c) the lipophilicity of the solute are mathematically explicit. 
The applicability of the model is shown with preliminary in situ rat intestinal 
absorption studies with prostaglandin F,,. 
REFERENCES 
BARR, W. H. & RIEGELMAN, S. (1970). J. Phurm. Sci. 59, 164. 
CRANE, R. K. (1975). In Intestinal Absorption and Malabsorption (T. 2. Csaky, ed.) p, 127. 
New York: Raven Press. 
FLYNN, G. L., Ho, N. F. H. & HIGUCHI, W. I. (1976). J. Phurm. Sci., 65, 154. 
Ho, N. F. H., HIGUCHI, W. I. & TURI, J. (1972). J. Pharm. Sci. 61, 192. 
MAGEE, W. E., ARMOUR, S. B. & MILLER, 0. V. (1973). Biochim. Biophys. Acta 306, 270. 
NAKANO, J., PRANCAN, A. V. & MORSY, N. H. (1973). Japan J. Pharmacol. 23, 355. 
PARKINSON, T. M. & SCHNEIDER, J. C. (1969). Biochim. Biophys. Actu 176,78. 
ROBERT, A., MAGEE, W. E., MILLER, 0. V. & NEZAMIS, J. E. (1974). Biochim. Biophys. 
Acta 348,269. 
UGOLEV, A. M. (1968). Physiology and Pathology of Membrane Digestion. New York: 
Plenum Press. 
UGOLEV, A. M. (1974). In Biomembranes: Intestinal Absorption, vol. 4A, Ch. 7 (D. H. 
Smyth, ed.). New York: Plenum Press. 
T.B. 13 
